Do utilization management controls for phototherapy increase the prescription of biologics? : PsoriasisSIMPSON, Gregory L; YELVERTON, Christopher B; RITTENBERG, Sheila et al.Journal of dermatological treatment. 2006, Vol 17, Num 6, pp 359-361, issn 0954-6634, 3 p.Article

Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapyCOIMBRA, S; OLIVEIRA, H; SANTOS-SILVA, A et al.British journal of dermatology (1951). 2010, Vol 163, Num 6, pp 1282-1290, issn 0007-0963, 9 p.Article

Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgarisPARSLEW, Richard; TRAULSEN, Jette.EJD. European journal of dermatology. 2005, Vol 15, Num 1, pp 37-39, issn 1167-1122, 3 p.Article

Oral vitamin D, still a viable treatment option for psoriasisKAMANGAR, Faranak; KOO, John; HELLER, Misha et al.Journal of dermatological treatment. 2013, Vol 24, Num 4, pp 261-267, issn 0954-6634, 7 p.Article

Kutane Nebenwirkungen molekular zielgerichteter Therapien = Cutaneous reactions to molecular targeted therapiesPFÖHLER, C; UGUREL, S.Hautarzt. 2008, Vol 59, Num 10, pp 814-820, issn 0017-8470, 7 p.Article